The Os odontoideum is a developmental anomaly of the axis in which the odontoid process is divided transversely. The Atlanto-axial dislocation due to Os odontoideum is presented. At first, we have performed the posterior atlanto-axial fusion with wire fixation. But the posterior fusion failed in realignment and did not adequately decompress the deformed cord by encroachment on its ventral surface. Next time, we have experienced further improvement following transoral decompression and anterior fusion.
Axis, Cervical Vertebra ; Decompression* ; Dislocations* ; Odontoid Process

The authors analyzed 11 cases of pineal region tumor in young male patients who had been treated at the Capital Armed General Hospital. So, the following results were obtained. 1) Due to the army distinctiveness, all cases were young male patients. 2) An unusual large proportion of pineal region tumor(26.2%) was noted. 3) Headache and vomiting were main presenting symptoms and the duration of symptoms was short. 4) The tumors were mainly presented as a round well-enchancing masses with calcification. Also, nearly all were associated with hydrocephalus. 5) MRI was very useful for the demonstration of tumor extent. 6) Based on the classification of pineal tumor, the tumors of germ cell origin were predominant(81.9%). 7) The extrapineal metastasis was frequent. 8) The tumor marker(alpha-FP and HCG) was postive in 4 cases(36.4%). 9) Germinoma showed excellent prognosis for the irradiation following a drainage procedure.
Arm ; Classification ; Drainage ; Germ Cells ; Germinoma ; Headache ; Hospitals, General ; Humans ; Hydrocephalus ; Magnetic Resonance Imaging ; Male ; Neoplasm Metastasis ; Pinealoma ; Prognosis ; Radiotherapy ; Vomiting

Background/Aims: Prokinetics such as mosapride citrate CR (conventional-release; Gasmotin) are commonly used in functional dyspepsia (FD). This study aims to evaluate the efficacy and safety of once-a-day mosapride citrate SR (DWJ1252), a sustained-release formulation of mosapride citrate, compared with mosapride citrate CR 3 times a day, in patients with FD. Methods: In this multicenter, randomized, double-blind, active-controlled, non-inferiority study, 119 patients with FD (by the Rome III criteria, 60 for mosapride citrate SR and 59 for mosapride citrate CR) were randomly allocated to mosapride citrate SR once daily or mosapride citrate CR thrice daily for 4 weeks in 16 medical institutions. Primary end point was the change in gastrointestinal symptom (GIS) score from baseline, assessed by GIS questionnaires on 5-point Likert scale after 4-week treatment. Secondary end points and safety profiles were also analyzed. Results: The study included 51 and 49 subjects in the mosapride citrate SR and mosapride citrate CR groups, respectively. GIS scores at week 4 were significantly reduced in both groups (mean ± SD: − 10.04 ± 4.45 and − 10.86 ± 5.53 in the mosapride citrate SR and mosapride citrate CR groups, respectively; P < 0.001), and the GIS changes from baseline did not differ between the 2 groups (difference, 0.82 point; 95% CI, − 1.17, 2.81; P = 0.643). Changes in GIS at weeks 2 and 4 and quality of life at week 4, and the improvement rates of global assessments at weeks 2 and 4, did not differ between the groups. Adverse events were similar in the 2 groups, and there were no serious adverse events. Conclusion In patients with FD, mosapride citrate SR once daily is as effective as mosapride citrate CR thrice daily, with a similar safety profile.